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Abstract
Ying Yang 1 (YY1) is a multifunctional Polycomb Group (PcG) transcription factor that binds to multiple enhancer binding
sites in the immunoglobulin (Ig) loci and plays vital roles in early B cell development. PcG proteins have important functions
in hematopoietic stem cell renewal and YY1 is the only mammalian PcG protein with DNA binding specificity. Conditional
knock-out of YY1 in the mouse B cell lineage results in arrest at the pro-B cell stage, and dosage effects have been observed
at various YY1 expression levels. To investigate the impact of elevated YY1 expression on hematopoetic development, we
utilized a mouse in vivo bone marrow reconstitution system. We found that mouse bone marrow cells expressing elevated
levels of YY1 exhibited a selective disadvantage as they progressed from hematopoietic stem/progenitor cells to pro-B, pre-
B, immature B and re-circulating B cell stages, but no disadvantage of YY1 over-expression was observed in myeloid lineage
cells. Furthermore, mouse bone marrow cells expressing elevated levels of YY1 displayed enrichment for cells with surface
markers characteristic of long-term hematopoietic stem cells (HSC). YY1 expression induced apoptosis in mouse B cell lines
in vitro, and resulted in down-regulated expression of anti-apoptotic genes Bcl-xl and NFkB2, while no impact was observed
in a mouse myeloid line. B cell apoptosis and LT-HSC enrichment induced by YY1 suggest that novel strategies to induce
YY1 expression could have beneficial effects in the treatment of B lineage malignancies while preserving normal HSCs.
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Introduction
Yin Yang 1 (YY1) is a ubiquitous and multifunctional zinc-
finger transcription factor that mediates multiple diverse functions.
YY1 can act as a transcriptional activator, repressor or initiator
protein depending upon DNA binding site context or cell type
[1,2,3]. Homozygous disruption of the yy1 gene in mice results in
peri-implantation lethality. Heterozygous knock-out mice show
growth retardation and some neurological defects [4]. Reduction
of YY1 levels impairs embryonic growth and viability in a dose-
dependent manner [5]. There is a tight correlation between YY1
dosage and cell proliferation, with deletion of the yy1 gene
resulting in cytokinesis failure and cell cycle arrest [5]. YY1 is also
implicated in lineage differentiation and cell growth control
[6,7,8], as well as in oncogenesis and other diseases such as
dystrophic muscle disease [6,9].
YY1 can bind the retinoblastoma (Rb) protein to accelerate cell
cycle progression to the S phase [8,10], can activate c-myc P1
promoter activity in Burkitt’s lymphoma [11], and can enhance
murine double minute 2 (mdm2)-mediated p53 inactivation thus
potentiating cellular proliferation and tumorigenesis [12]. On the
contrary, in human basal cell carcinoma YY1 shows repressive
activity at the GST locus and may prevent tumor progression
caused by the GSTM3 genotype [13]. Indeed, Lichy et al found a
marked decrease in YY1 binding in malignant HeLa/fibroblast
somatic cell hybrids when compared to non-tumor cells, [14] while
Austen and colleagues showed that YY1 is a negative regulator of
cell growth via potent inhibition of c-myc transforming activity
and possible involvement in tumor suppression [15]. These diverse
YY1 functions probably result from its ability to interact with
numerous proteins and complexes.
YY1 is the only known mammalian Polycomb Group (PcG)
protein with DNA binding specificity. We found that YY1 is
functionally similar to the apparently orthologous Drosophila PcG
protein, Pleiohomeotic (PHO) [16]. YY1 can repress transcription
in a PcG-dependent fashion, can recruit PcG proteins to DNA,
can correct phenotypic defects in PHO mutant flies, and can
control genes needed for development and differentiation
[17,18,19,20]. In mammals, PcG proteins are implicated in
Homeobox (Hox) gene regulation and stable silencing of specific
sets of genes through chromatin modifications. PcG proteins are
also involved in maintenance of embryonic and adult stem cells.
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30656The PcG protein Bmi-1 is necessary for hematopoietic stem cell
(HSC) self-renewal and can control cell proliferation
[17,21,22,23]. Similarly, the PcG protein EZH2 can prevent
HSC exhaustion [22] whereas Mel18 negatively regulates HSC
self-renewal [24]. As YY1 is a PcG protein, it may also play
important roles in HSC biology, but such roles have never been
explored.
B cell development involves progression from Lin
2Sca-1
+c-Kit
+
(LSK) progenitor cells through common lymphoid progenitors,
pro-B, pre-B, immature B, mature B, and plasma cell stages.
Transcription factors regulate cell fate determination through a
complex network required for development of early progenitors,
and for B cell lineage commitment, maturation, proliferation and
survival [8,25,26,27,28]. YY1 has long been believed to play an
important role in immunoglobulin (Ig) gene regulation because it
binds to numerous Ig enhancer elements including the Igk 39
enhancer, the heavy chain intron enhancer, and the heavy chain
39 enhancer [29,30]. The Shi laboratory showed that YY1 is also a
critical regulator of B cell development [31], as conditional knock
out of the yy1 gene in the B cell lineage results in an early B cell
defect with an almost complete block at the pro-B cell stage,
impaired VH to DHJH recombination, and reduced Ig locus
contraction [31,32].
Since conditional yy1 gene knock-out in the B cell lineage
profoundly impacts B cell development, various dosages of YY1
impact gene expression and development, and multiple PcG
proteins where previously demonstrated to play crucial roles for
hematopoietic stem cell self-renewal, we sought to explore the
impact of YY1 over-expression on hematopoietic development.
We utilized a mouse bone marrow reconstitution system to explore
whether elevated levels of YY1 would impact hematopoietic cell
development and growth. We found that elevated YY1 expression
resulted in a progressive selective disadvantage as cells matured to
the pro-B, pre-B, immature B and re-circulating B cell stages, but
had no detrimental effect on bone marrow myeloid lineage cells.
On the contrary, we observed an enrichment of YY1-expressing
cells in the Lineage
2, Sca-1
hi, c-Kit
hi cell fraction, containing
HSCs. This enrichment was particularly visible within the long-
term HSC (LT-HSC) compartment. YY1 over-expression in B cell
lines inhibited survival by inducing apoptosis, whereas apoptosis
was not observed in a myeloid line. Two anti-apoptotic genes, Bcl-
xl and NFkB2, were down regulated by elevated levels of YY1 in B
cell lines but not in a myeloid cell line confirming the pro-
apoptotic effect of YY1 in the B cell lineage.
Results
Conditional YY1 inactivation in the B cell lineage results in
developmental arrest at the pro-B cell stage [31]. Haplo-
insufficiency of YY1 can lead to numerous developmental defects
and two-fold changes in YY1 expression can alter the regulation of
many genes [4,5]. As the impact of elevated YY1 expression on the
B cell lineage is unknown, we set out to assess the effects of
elevated YY1 expression on B cell development using a bone
marrow transduction and reconstitution approach. For these
studies, we transduced C57BL/6 bone marrow progenitors with
retroviral vector alone (MigR1) or a retrovirus expressing Flag-
tagged YY1 (MigRI-FlagYY1). The MigR1 vector allows us to
track levels of YY1 expression by monitoring levels of green
fluorescent protein (GFP) expression from a bicistronic RNA
containing an internal ribosomal entry site. Thus, levels of GPF
expression correlate with levels of YY1 expression when using this
vector (Fig. S1A). In addition, we compared the level of YY1
expression in B lineage 38B9 pro-B cells and myeloid lineage 32D
cells. Cells were transduced with MigR1-FlagYY1 vector and
sorted into identical GFP low and GFP high gated fractions.
Equivalent amounts of lysates were analyzed on the same gel by
western blot with anti-YY1 antibody and anti-actin to serve as a
loading control so we could directly compare YY1 levels in the two
lineages. We found that myeloid cells expressed higher levels of
endogenous YY1 compared to B lineage cells (Fig. S1B left, lanes 1
and 4). As expected, transduction with MigR1-FlagYY1 resulted in
increased YY1 expression with the highest levels in the GPF high
fractions (Fig. S1B lanes 2,3,5,6). Quantitation of these data are
shown in Fig. 1B, right. Levels of total YY1 expression are overall
similar in the two lineages, but are higher in the myeloid cells due
to their higher level of endogenous YY1.
MigR1-Flag-YY1 or MigR1 transduced bone marrow cells were
transplanted into lethally irradiated C57BL/6 mice. Reconstituted
mice were subject to analysis from 10 weeks to 26 weeks post
injection. Both MigR1 and MigR1-Flag-YY1 transduced bone
marrow cells yielded efficient reconstitution efficiency at 10 weeks
post injection as evidenced by the high percentage of GFP positive
cells in the Lin
2Sca
hi c-Kit
hi (LSK) fraction (Fig. 1A). We isolated
GFP+ lymphoid cells by FACS from the blood of MigR1-FlagYY1
reconstituted mice, and performed western blots to determine the
level of exogenous YY1 protein compared to endogenous YY1
protein. In blood lymphocytes, exogenous Flag-tagged YY1
protein (Fig. S1C left, upper band) was expressed at an equivalent
level compared with endogenous YY1 (Fig. S1C left, lower band).
Exogenous expression levels were similar to levels observed in
transduced 32D myeloid cells (Fig. S1C, right). These experiments
(Figure S1) show that cells expressing MigR1-FlagYY1 reconstitute
well in recipient mice, that expression of YY1 is elevated in
MigRI-FlagYY1 transduced cells, that myeloid and B lineage cells
express similar levels of transduced YY1, and that GFP levels
correlate with YY1 expression levels.
YY1 over-expression results in a B lymphoid-specific
selective disadvantage
Between 10 to 26 weeks post bone marrow reconstitution,
recipient mouse bone marrow and spleen cells were stained and
analyzed by flow cytometry. For MigR1 reconstituted mice, the
percentage of GFP positive cells remained stable when comparing
bone marrow pro-B (B220
+CD43
+CD19
+AA4.1
+ IgM
2), pre-B
(B220
+CD43
2 IgM
2AA4.1
+), immature B (B220
+CD43
2Ig-
M
+AA4.1
+) and re-circulating B cells (B220
+CD43
2IgM
+AA4.1
2)
(Fig. 1A, left panel). However, as early as 10 weeks post
reconstitution, in MigR1-FlagYY1 reconstituted mice, there was
a progressive decrease in percentage of GFP positive cells from
75% in LSK (Lin
2Sca
hic-Kit
hi) cells, to 64% in pro-B, 54% in
pre-B, 50% in immature B, and 24% in re-circulating B cells,
respectively (Figure 1A, left panel, and Fig. 1B). In addition, there
was a significant and progressive leftward shift of GFP signal in
pro-B, pre-B, immature B, and re-circulating B cell pools
indicating a selection against high level YY1 expression in the B
cell lineage (Fig. 1A, left panel, and Fig. 1C). Consistent with less
pronounced effects of YY1 expression in early B lineage cells, there
was no noticeable difference in VDJ rearrangement of proximal
and distal VH genes in MigR1-FlagYY1 transduced animals
compared to MigR1 vector alone (Fig. S2).
At 26 weeks post reconstitution, there continued to be a
pronounced selection against cells expressing high levels of YY1 in
the B cell lineage as evidenced by an even more obvious decrease
of GFP percentages as well as leftward shifts of GFP signals
(Fig. 1A, right panel). MigR1-FlagYY1 reconstituted mice had
consistently lower percentages of GFP+ cells in bone marrow pro-
B, pre-B, immature B and re-circulating B cells compared with
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PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e30656Figure 1. Cells expressing high levels of YY1 are depleted in B cell populations. Lethally irradiated C57BL/6 mice were reconstituted with 5-
FU-treated C57BL/6 donor bone marrow cells transduced with MigR1-FlagYY1 or MigR1 vector alone. Recipient mice were subject to analysis at 10
weeks, 14 weeks, 18 weeks or 26 weeks post transplantation. (A) The top panel shows the cell gating strategy. Bone marrow cells were evaluated for
the presence of pro-B (B220
+CD43
+CD19
+AA4.1
+IgM
2), pre-B (B220
+CD43
2 IgM
2AA4.1
+), immature B (B220
+CD43
2IgM
+AA4.1
+), and re-circulating B
(B220
+CD43
2IgM
+AA4.1
2) cells. GFP+ percentages are listed in each B cell compartment in MigR1 or MigR1-FlagYY1 reconstituted mice 10 weeks (left
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ed mice had a substantially lower GFP mean fluorescence intensity
(MFI) among GFP+ bone marrow pro-B, pre-B, immature B and
re-circulating B lineages as compared with MigR1 reconstituted
mice (Fig. 1C). This provided quantitative evidence for the loss of
high YY1-expressing cells in these cell compartments. Thus high
levels of YY1 expression appear to be detrimental to developing
bone marrow B cell populations.
The YY1 inhibitory effect observed during B cell development
was not observed in bone marrow myeloid lineages. At 10 weeks
post reconstitution, the percentage of GFP positive cells remained
relatively stable in the myeloid lineage from 75% in the LSK
(Lin
2Sca
hic-Kit
hi) pool (Fig. 1A) to 71% in bone marrow CMP
(Lin
2 Sca
2 c-Kit
hi CD16/32
lo CD34
+), 73% in bone marrow
GMP (lin
2 c-kit
hi Sca
2 CD16/32
hi CD34
+), and 82% of bone
marrow myeloid cells (Gr-1
+CD11b
+) (Fig. 2A, left panel). GFP
expression in splenic Gr-1
+CD11b
+ cells also remained relatively
high at 63% (Fig. 2A, left panel). Similarly, at 26 weeks post
reconstitution, we did not observe any detrimental effects of high
levels of YY1 on bone marrow myeloid lineages (Fig. 2A, right
panel). Compared to 10 weeks post-reconstitution, bone marrow
CMP GFP positive cells increased from 71% to 82%, GMP
increased from 73 to 84%, and Gr-1
+CD11b
+ cells increased from
82% to 91% (Fig. 2A). MigR1-Flag YY1 and MigR1 vector
reconstituted mice had similar percentages of GFP positive cells in
CMP, GMP and myeloid compartments (Fig. 2B), and MigR1-
FlagYY1 and MigR1 vector reconstituted LSK, GMP and
myeloid cells showed similar MFI among GFP+ cells, although
there was a slight positive effect of YY1 on MFI in CMPs (Fig. 2C).
The distinct effects of YY1 expression on the percentage of GFP+
cells among B cell and myeloid cell populations is summarized in
Fig. 2D.
Cells expressing elevated YY1 are enriched in LT-HSC
cells
PcG proteins are involved in hematopoietic development, stem
cell self-renewal and cell proliferation. As YY1 is a PcG protein
[17], we hypothesized that YY1 over-expression might also
influence HSC biology. Consistent with this hypothesis, we
observed an enrichment of MigRI-FlagYY1 transduced cells in
the LSK fraction containing HSCs (Figure 1B). At 10 weeks post
reconstitution, 75% of cells in the LSK pool were GFP positive
and this increased to 90% by 26 weeks, indicating enrichment of
cells expressing high levels of YY1 in this progenitor compartment
(Fig. 1A). Within the LSK pool we further examined the
phenotypically defined LT-HSC population by analysis of CD48
and CD150 cell surface markers [33], By comparing the
percentages of LT-HSCs among GFP+ versus GFP2 LSK cells,
we observed a higher percentage of LT-HSCs within the GFP+
LSK population of YY1 reconstituted mice as compared to the
GFP2 population (Fig. 3A). Conversely, we examined the
percentage of GFP expression in phenotypically defined LT-
HSCs, short-term HSCs, common myeloid progenitors (CMPs),
and granulocyte-macrophage progenitors (GMPs). An enrichment
for GFP+ cells was observed specifically in the LT-HSC
compartment of MigR1-FlagYY1 reconstituted mice but there
was no difference in CMP and GMP populations (Fig. 3B). These
data indicate that cells expressing high levels of YY1 are enriched
in the bone marrow LT-HSC population of MigR1-FlagYY1
reconstituted mice.
YY1 inhibits B cell growth in vitro
To further explore the inhibitory activity of YY1 expression in
the B cell lineage, we tested the effect of YY1 expression on the
growth of various B cell lines. We reasoned that if YY1 inhibited
B cell growth, cells transduced with MigR1-FlagYY1 should be at
a selective growth disadvantage in culture and should progres-
sively decrease in relative percentage compared to untransduced
cells and vector control transduced cells. We retrovirally
transduced murine pro-B cell line 38B9, murine pre-B cell line
3-1, murine plasmacytoma cell line S194, and Il-7 cultured
primary bone marrow B cells with MigR1-FlagYY1 or empty
MigR1 vector. MigR1 vector transduced GFP-positive cells
proliferated at a rate similar to the untransduced GFP-negative
cells as indicated by the stable percentage of GFP-positive cells at
different time points after transduction (Fig. 4A). In contrast, the
percentage of MigR1-YY1 transduced GFP positive cells declined
dramatically in murine pro-B, pre-B, plasmacytoma, and Il-7
cultured bone marrow B cells, indicating growth arrest and/or
cell death (Fig. 4A). Since our in vivo data showed that YY1
overexpression was detrimental to B cells but not myeloid cells
(Figs. 1 and 2), we transduced murine myeloid cell line 32D with
MigR1-YY1 or MigR1 empty vector. Consistent with our in vivo
data, there was no decline of GFP-positive percentages in YY1
expressing myeloid cells over time (Fig. 4B). Thus, similar to the
case in vivo, we observed no negative impact of elevated YY1
levels on myeloid cell growth.
To test the impact of elevated YY1 on B-lymphomagenesis in
vivo, the Myc-over-expressing B-lymphoma Myc3 [34] was
infected with either MigR1-YY1 or MigR1 vector. When
evaluated in vitro, YY1 transduced GFP positive cells declined
dramatically over time (Fig. 4C). To test YY1 inhibitory effects in
vivo, the mixture of transduced and uninfected cells was injected
subcutaneously in syngeneic animals to produce tumors. Two
weeks post-injection, the resulting tumors were analyzed by flow
cytometry and percentages of GFP-positive cells were determined
again. For MigR1 infected cells, the percentage of GFP-positive
cells remained unchanged (Fig. 4D). However, there was a 3-fold
decrease in the percentage of GFP-positive cells in MigR1-
FlagYY1 transduced Myc3 cells (Fig. 4D). We also tested two
human pre-B acute lymphoblastic leukemia (ALL) lines (697 and
JM-1) to determine whether they would also respond to elevated
YY1 expression similar to murine B cell lines. The two cell lines
were transduced with MigR1 or MigR1-FlagYY1 and the
percentage of GFP-positive cells was plotted over 10 days. Again,
there was a drop in GFP-positive cells over time in the YY1-
elevated samples, similar to the case with the murine B lymphoma
cell lines (Fig. 4E). Thus, in all cases, YY1 expression resulted in a
disadvantage among B lineage cells, but had no impact on myeloid
cells.
panel) or 26 weeks (right panel) post reconstitution. (B) MigR1-FlagYY1 reconstituted mice have lower GFP+ percentages compared with MigR1
control mice. GFP+ percentages shown for individual mice in the LSK, pro-B, pre-B, immature B and re-circulating B cell compartments at 14 or 18
weeks post reconstitution. Each data point represents a GFP+ percentage of an individual mouse. (C) GFP MFI decreases throughout B cell
development in MigR1-FlagYY1 reconstituted mice. GFP MFI of bone marrow pro-B, pre-B, immature B and re-circulating B cells in MigR1-FlagYY1 and
MigR1 reconstituted mice are normalized to GFP MFI in the LSK population of each group (MigR1 versus MigR1-FlagYY1). Each dot represents the MFI
of an individual mouse 14 or 18 weeks post reconstitution. In (B) and (C), cell fractions marked with one or two asterisks show significant differences
between MigRI and MigR1-FlagYY1 populations at P,0.05 and 0.01, respectively.
doi:10.1371/journal.pone.0030656.g001
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To determine the mechanism of YY1-induced selective
disadvantage in B cells, we assessed whether elevated YY1
expression affected cell growth parameters. MigR1 and MigR1-
YY1 transduced 38B9 cells were evaluated for DNA content by PI
staining. Comparing MigR1-FlagYY1 to empty vector there was
little difference in G1/S, G2, or M stage profiles (Fig. 5A).
Similarly, there was no difference in Budr incorporation
comparing GFP+ and GFP2 38B9 cells transduced with
MigRI-YY1 (Fig. 5B). However, we observed a 7 fold increase
in the sub-G1 phase cell population consistent with a substantial
increase in apoptotic cells (Fig. 5A). MigR1-FlagYY1 and MigR1
transduced 38B9 pro-B cells were stained with the dead cell
exclusion dye 7-AAD and the apoptosis indicator AnnexinV.
Interestingly, we observed a substantial increase of early apoptotic
cells (AnnexinV
+, 7AAD
2) in MigR1-FlagYY1 transduced cells as
compared to those transduced with MigR1 empty vector (Fig. 5C).
We also tested the impact of elevated YY1 on the apoptosis
marker protein, cleaved caspase-3. In MigR1-FlagYY1 transduced
38B9 pro-B cells, increased YY1 expression led to a 6.6 fold
elevation of cleaved caspase-3 (Fig. 5D). As a negative control, we
transduced the murine myeloid cell line 32D with MigR1-
FlagYY1 or MigR1 and GFP-positive cells were sort-purified.
Increased YY1 expression did not change the level of cleaved
caspase-3 when comparing MigR1-FlagYY1 expressing cells to
empty vector MigR1 expressing cells (Fig. 5E). Thus, consistent
with our in vivo results, forced expression of YY1 did not cause
apoptosis in myeloid cells.
To gain further insight into YY1 induced B cell-specific
apoptosis, we used a genome-wide microarray approach to
identify YY1 target genes in murine pro-B cells. We performed
microarray analyses on 38B9 pro-B cells transduced either with
MigR1-FlagYY1 or MigR1 vector control. This comparison
enabled us to identify approximately 700 genes whose expression
was affected by YY1. RT-PCR analyses for a subset of transcripts
confirmed our microarray results as over 80% of transcripts
matched closely in fold increase or decrease in the presence of
overexpressed YY1 (Fig. S3; see also Fig. 6A).
Evaluation of identified transcripts using David Bioinformatics
Resources (NIAID) and the KEGG Functional Annotation Chart
revealed that genes involved in cell cycle control and BCR-ABL
signaling were down-regulated by YY1. The complete list of YY1-
responsive genes is provided in Table S3. Consistent with the
YY1-induced apoptotic effect we observed in B cells, several anti-
apoptotic related genes (NFkB2 and Bcl-xl) were deregulated by
elevated YY1 expression. We found 4 fold decreases in NFkB2
and Bcl-xl transcripts in MigR1-FlagYY1 transduced cells
compared to MigR1 vector alone (Fig. 6A) and a corresponding
2.4 fold decrease in the levels of NFkB2 and 3.4 fold decrease in
Bcl-xl proteins (Fig. 6B). On the contrary, in MigR1-FlagYY1
transduced 32D myeloid cells we observed the opposite results. In
contrast to YY1-induced down regulation of Bcl-xl and NFkB2 in
B cells, we observed a 4.5-fold increase in Bcl-xl transcripts and
2.6-fold increase in Bcl-xl protein in 32D myeloid cells. Similarly,
we observed a 1.5-fold increase of NFkB2 transcripts but no
change of NFkB2 protein in 32D myeloid cells (Fig. 6C and D).
Thus, elevated YY1 results in down regulation of anti-apoptotic
genes in B cells but not in myeloid cells.
The mechanism of down regulation of NFkB2 and Bcl-xl by
YY1 in B cells could be either direct or indirect. ChIP assays were
performed to determine if YY1 bound directly to the Bcl-xl and
NFkB2 promoters. Multiple primer sets were designed covering
approximately 1 kb of the Bcl-xl and NFkB2 promoters,
respectively. Whereas YY1 was clearly enriched at the positive
control rpL30 promoter in 38B9 pro-B cells, we did not detect
obvious enrichment of YY1 at either Bcl-xl or NFkB2 promoters
above that observed at the negative control b-actin promoter
(Figure S4). Thus, YY1 may influence these two anti-apoptotic
genes indirectly, or YY1 might bind to other DNA sequences that
regulate these two genes. Consistent with the former option,
overexpression of NFkB2 and Bcl-xl either separately or together
failed to reverse the pro-apoptotic effect of YY1 overexpression
(data not shown). Thus, reduced NFkB2 and Bcl-xl proteins in
YY1 overexpressing B cells appears to be a consequence of YY1
apoptotic induction rather than due to direct regulation of the
NFkB2 and Bcl-xl genes. None-the-less, reduced levels of these
proteins confirm that YY1 overexpression induces apoptosis in B
lineage cells.
Discussion
The functional consequences of YY1 regulation in hematopoi-
etic cell development are poorly understood. Conditional knock-
out of YY1 in the B cell lineage by action of mb1-driven CRE
results in arrest at the pro-B cell stage and impairment of
immunoglobulin distal V gene rearrangement [31]. Loss of YY1
may have an impact on both immunoglobulin locus contraction
needed for rearrangement of the most distal V genes, as well on
cell proliferation [31,32]. Other investigators have shown that
YY1 can inhibit neutrophil differentiation both in vivo and in
vitro [35]. In this study, we used bone marrow transduction and
reconstitution to investigate the impact of elevated YY1
expression on the B cell and myeloid hematopoietic compart-
ments in vivo. Significantly, we found that forced expression of
YY1 resulted in selective disadvantage as cells developed within
the B cell lineage. We observed a progressive decline in the
percentage of YY1-transduced (GFP positive) cells at each
successive B cell stage, and the GFP MFI signal progressively
decreased indicating selection against cells expressing high levels
of YY1 (Figs. 1 and 2). The inhibitory effect of YY1 on B cell
development was not caused by a non-specific toxic effect of
Figure 2. High levels of YY1 do not affect myeloid lineage development. Chimeric mice were prepared as described in Fig. 1. Recipient mice
were subject to analysis at 10 weeks, 14 weeks, 18 weeks or 26 weeks post transplantation. (A) The top panel shows the cell gating strategy. Bone
marrow cells were evaluated for the presence of CMP (lin
2 c-kit
hi Sca
2 CD16/32
lo CD34
+), GMP (lin
2 c-kit
hi Sca
2 CD16/32
hi CD34
+), and myeloid (Gr-
1
+CD11b
+) cells. GFP+ percentages are listed in each cell compartment in MigR1 or MigR1-FlagYY1 reconstituted mice 10 weeks (left panel) or 26
weeks (right panel) post reconstitution. (B) GFP+ percentages of MigR1-FlagYY1 reconstituted mice are the same as MigR1 control mice in myeloid
lineage cells. GFP+ percentages are shown for individual mice in the LSK, CMP, GM and myeloid cells in reconstituted mice 14 or 18 weeks post
reconstitution. Each data point represents a GFP+ percentage of an individual mouse. (C) GFP MFI remains stable throughout myeloid cell
development in MigR1-FlagYY1 reconstituted mice. GFP MFI of bone marrow LSK, CMP, GMP and myeloid cells in MigR1-FlagYY1 and MigR1
reconstituted mice are normalized to GFP MFI in the LSK population of each group (MigR1 versus MigR1-FlagYY1). Each dot represents the MFI of an
individual mouse 14 or 18 weeks post reconstitution. (D) Cells expressing high levels of YY1 experience negative selection in the B cell lineage but not
the myeloid lineage. GFP+ percentages of CMP, GMP, myeloid, pro-B, pre-B, immature B and re-circulating B cells are normalized to the GFP+
percentage of bone marrow LSK cells. Mean and standard error of the mean are shown. In B, C, and D, cell fractions marked with one or two asterisks
show significant differences between MigRI and MigR1-FlagYY1 populations at P,0.05 and 0.01, respectively.
doi:10.1371/journal.pone.0030656.g002
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developed normally (Fig. 2). In vitro studies confirmed the in vivo
results showing selective disadvantage of high YY1 expression in
B lineage cell lines, but not in myeloid cell line 32D. Thus, while
YY1 over-expression leads to growth disadvantage in B lineage
cells, there is no negative impact on myeloid cells. Our study is
the first to show that YY1 over-expression negatively impacts B
cell development.
It is interesting that loss of YY1 [31] and overexpression of YY1
(our results here) both result in altered B cell development. This
situation is somewhat reminiscent of the impact of overexpression
verses knock-out of transcription factor GATA-3. GATA-3 is
essential for T cell development and knock-out severely impacts
hematopoiesis [36,37,38]. However, overexpression of GATA-3
also blocks lymphoid and T lineage development [39,40]. Thus,
YY1 yields a similar scenario in which both loss of, and
overexpression of YY1 impacts B cell development. However,
the phenotypes of these two experimental systems are quite
different. YY1 conditional knock-out results in arrested B cell
development at the pro-B cell stage and reduced distal VH gene
Figure 3. Cells expressing high levels of YY1 are enriched in the LT-HSC cell population. Chimeric mice were made as described in Figs. 1
and 2. (A) MigR1-FlagYY1 reconstituted mice show a relative enrichment in the LSK fraction. MigRI and MigR1-FlagYY1 reconstituted bone marrow
cells were sorted into GFP2 and GFP+ populations and the percentage of LSK cells in each fraction are plotted. (B) YY1 expressing cells are enriched
in the LT-HSC fraction but not in the ST-HSC, CMP, or GMP fractions. In (A) and (B), cell fractions marked with two asterisks show significant
differences between MigRI and MigR1-FlagYY1 populations at P,0.01.
doi:10.1371/journal.pone.0030656.g003
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B cell lineage progress past the pro-B cell stage and show normal
VH gene rearrangement. However, YY1 overexpressing cells show
reduced numbers of B cells at later stages of B cell development
and show a progressive selection against cells expressing high levels
of YY1. The reduction is most significant past the pro-B cell stage.
Our microarray data indicate that YY1 overexpression impacts
apoptosis related genes as well as growth control genes. Perhaps
most relevant is the ability of YY1 to inhibit expression of cyclin
D3. This cyclin is very important for early B cell development and
particularly for the proliferative expansion of cells between the
pro-B and pre-B cell stages [41]. Knock-out of cyclin D3 causes a
significant drop in cells progressing to the pre-B cell stage resulting
in reduced cell numbers past the pro-B cell stage [41]. This is
similar to the drop we observe in our YY1 overexpression studies.
Thus, YY1 may inhibit cyclin D3 expression leading to reduction
in the proliferative burst and reduced differentiation to the pre-B
cell stage.
Figure 4. Transduction with MigR1-FlagYY1 results in selective disadvantage in the B cell lineage in vitro and in vivo, but not in
myeloid cells. (A) Murine pro-B cell line 38B9, pre-B cell line 3-1, plasmacytoma cell line S194 and Il-7 cultured murine bone marrow cells were
retrovirally infected with MigR1-FlagYY1 or MigR1 empty vector. Percentage of GFP positive cells was checked every two days by flow cytometry.
Percentages of GFP positive cells were normalized to the level at 48 hours post-transduction. (B) Murine myeloid cell line 32D was transduced by
MigR1-FlagYY1 or MigR1 retrovirus vectors. Percentage of GFP positive cells was checked every other day by flow cytometry for 10 days. Percentages
of GFP positive cells were normalized to the level on day 4 post-transduction. (C) Myc3 B-lymphoma cells were transduced with MigR1-YY1 or MigR1
control vector. Percentage of GFP positive cells was checked every two days by flow cytometry. Percentages of GFP positive cells were normalized to
the level on day 2 post-transduction. (D) Two days post infection, GFP+ percentages of Myc-3 cells were monitored by flow cytometry (pre-injection)
and transduced Myc3 cells were then injected into syngeneic mice subcutaneously. The number of GFP positive Myc3 cells in each sample was then
analyzed after tumor development two weeks post-injection. Percentages of GFP positive cells were normalized to the level on day 2 post-
transduction. E, Human pre-B ALL cell lines 697 and JM-1 were transduced by MigR1-YY1 and MigR1 retrovirus vectors. Percentages of GFP positive
cells were normalized to levels on day 4 post-transduction. The data represent the mean and standard error of the mean from three independent
experiments. In each panel, cell fractions marked with one or two asterisks show significant differences between MigRI and MigR1-FlagYY1
populations at P,0.05 and 0.01, respectively.
doi:10.1371/journal.pone.0030656.g004
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development and expansion of late stage germinal center B cells
[42,43]. Interestingly, cyclin D3 knock-out does not impact cell
proliferation in vitro, but results in failed proliferative expansion of
late stage germinal center B cells [42,43]. Thus, the impact of YY1
overexpression on reduced B cell numbers past the pro-B cell stage
may at least partially relate to inhibition of cyclin D3 which is
exquisitely important for two proliferative expressions in the B cell
lineage.
Others have also shown that modulation of YY1 expression
leads to altered expression of genes involved in cell cycle
regulation, mitosis and cytokinesis, DNA replication, apoptosis,
and cell growth [5]. For instance, complete ablation or knock-
down of YY1 leads to growth inhibition in embryonic fibroblasts,
HeLa cells, DT40 cells, and embryonic carcinoma cells, [5,12,44].
However, YY1 expression can similarly regulate cell growth by
interaction with Rb [8,12,44]. YY1 can also impact senescence by
regulating p16
INK4a [45], and can increase HoxB7 expression
directly involved in tumor progression [46].
The negative impact of YY1 on B cell development could also
be due to disrupted stoichiometry of YY1 in multiple protein
complexes such as the PcG and INO-80 complexes, or due to
interactions with regulatory proteins such as p53, c-myc, histone
acetyltransferases, and histone deacetylases [2,12,17,47]. Thus,
over-expression of YY1 could influence protein complex formation
leading to alterations in cell function. The negative impact of
elevated YY1 levels on B cell development could also be the
consequence of growth inhibition. However, our in vitro data did
not reveal changes in cell cycle progression. Instead, a fraction of
cells underwent apoptosis. Our in vitro results are most consistent
with YY1 expression inducing increased apoptosis in B cells, but
not in myeloid cells. Our study is the first to show that YY1 has a
pro-apoptotic function in B cells.
In vivo, additional YY1 effects on stem cells and lineage
differentiation are likely to be important. Unlike the case in B cells,
YY1 expression resulted in enrichment of phenotypically defined
LT-HSCs and granulocyte lineage cells. By 26 weeks post
reconstitution, cells expressing high levels of YY1 constituted
90% of the LSK population and 91% of the bone marrow Gr-1+
population. The percentage of YY1-expressing reconstituted LT-
HSCs and myeloid cells was substantially higher compared with
MigR1 vector reconstituted LT-HSC indicating a positive
selection for high levels of YY1 expression. These are interesting
results because they suggest that elevated levels of YY1 expression
might be beneficial for HSC function and may enhance
differentiation to the myeloid lineage at expense of the B lymphoid
lineage. This is reminiscent of a similar effect by transcription
factor PU.1 [48].
Epigenetic states are implicated in controlling various HSC
populations such as LT-HSC and ST-HSC, and YY1
expression may function to stabilize the LT-HSC chromatin
phenotype. Alternatively, YY1 might function as a traditional
transcriptional activator or repressor to regulate specific genes
involved in cell cycle control and stem cell function. In
preliminary studies we found that YY1 expression correlated
with elevated c-kit expression in LSK cells (unpublished data).
Thus, YY1 might regulate genes involved in maintenance of the
HSC phenotype and self-renewal. Clinical strategies to enhance
YY1 expression could thus preserve, or even enhance,
hematopoietic reconstitution.
Figure 5. High levels of YY1 induce apoptosis in B cells but not in myeloid cells. (A) MigR1-FlagYY1 and MigR1 transduced 38B9 cells were
stained with propidium iodide and the percentage of cells at each phase of the cell cycle were determined by flow cytometry. C, Cleaved caspase 3 is
up regulated in MigR1-FlagYY1 transduced pro-B cell line. MigR1-YY1 and MigR1 transduced 38B9 cell lysates were immunoblotted for cleaved
caspase 3 and YY1. b-actin was used as a loading control. (B) YY1 overexpression does not change the percentage of cycling cells. 38B9 cells were
transduced with MigR1-YY1, sorted by FACS into GFP+ and GFP2 populations and incubated with Brdu to measure DNA synthesis. (C) Murine pro-B
cell line 38B9 was infected with MigR1-YY1 or MigR1 vectors such that 90% of cells were transduced. Cells were stained with Annexin V-APC and 7-
AAD, and early apoptotic cells (Annexin-V+ and 7-AAD2) were determined by flow cytometry 48 hours post infection. Percentages of apoptotic cells
were normalized to percentage of apoptotic cells of MigR1 vector only infected cells. Mean and standard error of the mean are shown. The asterisk
indicates significant differences between MigRI and MigR1-FlagYY1 populations at P,0.05. (D) Cleaved caspase 3 is not up regulated in a MigR1-
FlagYY1 transduced myeloid cell line. Murine myeloid cell line 32D was transduced with MigR1-FlagYY1 or MigR1 vectors and GFP positive cells were
isolated by FACS. Cell lysates made from sorted cells were immunoblotted for cleaved caspase 3 and YY1. b-actin was used as a loading control. The
upper band indicates the Flag-tagged exogenous YY1 and the lower band is endogenous YY1.
doi:10.1371/journal.pone.0030656.g005
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silencing of specific gene sets through chromatin modifications and
dynamic reprogramming of epigenetic states. Many PcG proteins
including Bmi-1, EZH2, Rae28, and Mel18 are involved in HSC
function [22,23], and forced expression of PcG protein EZH2 can
prevent HSC exhaustion [22]. YY1 is the only mammalian PcG
protein with specific DNA binding ability, and YY1 can recruit
PcG proteins to specific DNA sites causing subsequent trimethyla-
tion of histone H3 on lysine 27 [18,20]. Thus, forced expression of
YY1 might change gene expression profiles by altering global
chromatin structure.
Dysfunction of PcG proteins has been argued to contribute to
the generation of cancer stem cells implying that PcG proteins
provide potential targets for anticancer therapy [49,50,51]. For
instance, loss or knock-down of PcG protein Ezh2 causes loss of
cell growth and the transformed phenotype of prostate cancer cells
[52]. Thus, the enrichment of cells expressing high levels of YY1 in
the LT-HSC cell population argue that YY1 might be involved in
cancer stem cell function and therefore could be a potential
therapeutic target for some hematopoietic malignancies. The
finding that transcription factor YY1 differentially controls
hematopoietic development provides rationale for multiple future
studies on the effect of YY1 on stem cell biology, lineage
development, and growth control.
Materials and Methods
All work involving animals complied with all federal, state, and
local laws, and was done with approval and oversight of the
University of Pennsylvania Institutional Animal Care and Use
Committee under protocol 803080.
Retroviral constructs
The flag-tagged YY1 cDNA sequence encoding the complete
414 amino acid protein was cloned into the HpaI site of GFP-
expressing MSCV-IRES-GFP vector (MigR1) by blunt end
ligation. High titer retroviral supernatants were prepared following
transient transfection of HEK293 cells. Retroviral envelopes with
ecotropic host ranges (pHIT123, for murine cells and pHIT 456
for human cells) were used.
Bone marrow transduction and transplantation
Bone marrow cells were harvested from 6 to 8 week-old
C57BL/6 or mb1-CRE yy1
f/f mice 4 days after intravenous
injection of 250 mg/kg 5-fluorouracil (5-FU). Cells were cultured
overnight in DMEM plus 10% fetal bovine serum and L-
Glutamine, with IL-3 (6 ng/ml), IL-6 (5 ng/ml), and SCF
(100 ng/ml), then washed and resuspended in retroviral superna-
tant containing polybrene (4 mg/ml) and the same cytokine
Figure 6. Anti-apoptotic genes NFkB2 and Bcl-xl are down regulated by YY1 in murine pro-B cells but not in murine myeloid cells.
(A) NFkB2 and Bcl-xl are down regulated at the transcript level in murine 38B9 pro-B cells. RT-PCR analyses of NFkB2 and Bcl-xl mRNA levels relative
to hprt are plotted for MigR1-YY1 or MigR1 transduced 38B9 cells. The data represent the mean and standard error of the mean for three
independent experiments. (B) NFkB2 and Bcl-xl are down regulated by YY1 at the protein level in murine 38B9 pro-B cells. Cell lysates from MigR1-
YY1 or MigR1 transduced 38B9 cells were immunoblotted for Bcl-xl, NFkB2 and YY1. b-actin was used as a loading control. (C) NFkB2 and Bcl-xl are up
regulated at the transcript level in murine myeloid cell line 32D. GFP positive MigR1-YY1 and MigR1 transduced murine myeloid cell line 32D samples
were isolated by FACS. Levels of NF-kB2 and Bcl-xl transcripts were determined by RT-PCR and hprt was used as an internal control and for
normalization. The data represent the mean and standard error of the mean from three independent experiments. (D) GFP positive MigR1-YY1 and
MigR1 transduced murine myeloid cell line 32D samples were isolated by FACS. Cell lysates were made from sorted cells and immunoblotted for
NFkB2, Bcl-xl and YY1. b-actin was used as a loading control. Mean and standard error of the mean are shown. Asterisks indicate significant
differences between samples at P,0.05.
doi:10.1371/journal.pone.0030656.g006
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round of spin infection was performed 24 hours following the first
one. At least 5610
5 cells were injected intravenously into lethally
irradiated (9 Gy) recipient C57BL/6 mice. Antibiotic containing
drinking water was provided for recipient mice for two weeks post
transplantation.
Cell cultures
HEK293 cells [53] were maintained in DMEM with 10% FBS.
Murine pro-B-cell line 38B9 and pre-B-cell line 3-1 [54] were
cultured in RPMI 1640 supplemented with 10% fetal bovine serum
(FBS) and 2-mercaptoethanol. Murine plasmacytoma cell line S194
(American Type Culture Collection) was cultured in DMEM with
10% horse serum. Myc3 B lymphoma cells [55] were cultured on a
monolayer of gamma-irradiated S17 feeder cells [56] as described
previously [55,57]. Murine myeloid cell line 32D (American Type
Culture Collection) was cultured in IMDM with 10% FBS, 10%
WEHI-3Bsupernatant and antibiotics. Human pre-B ALL cell lines
697 [58] and JM-1 (American Type Culture Collection) were
cultured in C10 lymphocyte media as previous described [59].
Primary B cell cultures
Bone marrow cells from C57BL/6 mice were isolated, plated
onto OP9 feeder cells and were cultured in IMDM with 10% FBS,
10 ng/mL IL-7, 50 micromolar 2-mercaptoethanol, 16 L-
glutamine, 16 non-essential amino acids and 16 penicillin/
streptomycin. Ten days later, 90% of bone marrow-derived cells
were B220
+IgM
2CD43
+ by flow cytometry.
Antibodies and flow cytometry
Antibodies for FACS analyses were obtained from BD
Biosciences-Pharmingen or eBioscience and are as follows:
CD19 (1D3), c-kit (2B8), Sca-1/Ly-6A/E (E13-161.7), B220
(RA3-B2), Ter119, CD11b, Gr-1/Ly6G, CD16/32, CD34,
CD43, AA4.1, sIgMb, CD21, CD 23, CD4, CD8 alpha, TCR
beta, NK1.1, and CD25. Acquisition was performed on FACS
Calibur FACSCanto or LSRII (BD). Sorting was performed with a
FACSAriaII (BD). Data were analyzed with BD FACStation or
FlowJo software.
Western blots
Total cell extracts were prepared in 26 SDS sample buffer
(Biorad). Sodium dodecyl sulfate-polyacrylamide gel electropho-
resis, western blotting, and peroxidase-based chemiluminescence
detection were performed according to standard laboratory
protocols. Antibodies were purchased from Santa Cruz (YY1,
H414), BD Biosciences (Bcl-xl, 2H12), or Cell Signaling (NFkB2,
4882; cleaved caspase-3, Asp175). Bands were quantified by using
ImageJ software.
PCR Detection of Ig Rearrangement
Genomic DNA from sorted GFP
+ splenic B cells from MigR1 or
YY1 reconstituted mice were made by DNeasy Blood & Tissue kit
(QIAGEN). For heavy chain rearrangements, DNA samples were
amplified by PCR reactions with primers described previously
[60]. PCR products were separated on 1.5% agarose gels and
visualized by Southern blot with an oligo probe (5-AGC CTT
CAG GAC CAA GAT TCT CTG CAA ACG-3) detecting the
region upstream of JH3.
Quantitative real-time PCR
RNA was made by the Trizol procedure according to the
manufacturer’s specifications (Invitrogen) and subjected to the
reverse transcriptase-polymerase chain reaction (RT-PCR) proce-
dure. Murine primers for YY1 were: sense CCCACGGTCCCA-
GAGTCCA and anti sense TGTGCGCAAATTGAAGTC-
CAGT. Other primers for RT-PCR are listed in Table S1. Hprt
was used as an internal control or normalization. Hprt primers
were: sense CTCCTCAGACCGCTTTTTCC and antisense TA-
ACCTCCTTCATCATCGCTAATC. All amplifications crossed
intron-exon boundaries to exclude genomic DNA amplification.
ChIP
Chromatin immunoprecipitation (ChIP) was carried out as
previously described [61]. For all ChIP experiments, quantitative
PCR analyses with primers shown in Table S2 were performed by
real-time PCR using a Roche Lightcycler 1.5. Relative increases
were calculated on the basis of pre-immune ChIP sample
quantitative PCR values. Relative enrichments for each region
are presented as the percentage of input.
BrdU assay
BrdU was directly added into the culture medium to obtain a
final concentration of 50 mM for 45 minutes. Cells were then
fixed, permeabilized, and stained with APC conjugated anti-BrDU
antibody following the manufacture’s instructions (BrdU flow kit,
BD Pharmingen). 7-AAD was added cells for FACS analyses.
Microarray analyses
Murine pro-B 38B9 cells were retrovirally infected with MigR1
vector or MigR1-FlagYY1 such that nearly 100% of the cells were
transduced. 48 hours post infection, RNA samples were prepared
using Trizol reagent (Invitrogen), and cDNA was prepared using
the Superscript II kit (Invitrogen). The cDNAs were subjected to
hybridization with a DNA-Chip mouse genome 430A array
(Affymetrix) using the University of Pennsylvania Microarray
Facility’s standard protocol (http://www.med.upenn.edu/microarr/
DataAnalysis/Affymetrix/methods.htm). Data analyses were per-
formed with Affymetrix Microarray Suite 5.0. The work complies
with MIAME guidelines and has been deposited with ArrayExpress
(accession number E-MTAB-679).
Supporting Information
Figure S1 GFP levels correlate with YY1 expression,
and exogenous YY1 is well expressed in chimeric mice.
(A) 38B9 cells were tranduced with MigR1-FlagYY1 and four days
later cells were sorted into low, middle, and high GFP-expressing
populations. Cell lysates were evaluated by western blot with anti-
YY1 antibody, and blots showed that YY1 expression correlates
with the level of GFP expression. (B) 32D myeloid and 38B9 pro-B
cells were transduced with MigR1-FlagYY1 and sorted into GFP
low and GFP high fractions of identical intensity between the two
cells types. Equivalent amounts of cell lysates from untransduced
(endogenous) and GFP sorted samples were evaluated by western
blot on the same gel with anti-YY1 antibody (414; Santa Cruz
Biotechnology) or anti-actin antibody and signals were quantitated
with Image J software. The left panel shows the western blot data
from the same gel probed at the same time with the same
antibodies. The right panel shows Image J quantitation.
Endogenous YY1 levels are higher in myeloid cells and increase
to slightly higher levels after MigRI-FlagYY1 transduction
compared to 38B9 pro-B cells. (C) Exogenous YY1 is expressed
at similar protein levels as endogenous YY1 in B cells. GFP+
lymphocytes were sorted from the blood of MigR1-FlagYY1
reconstituted mice 14 weeks post reconstitution and crude cell
lysates were made. Western blot was performed for detection of
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band indicates Flag-tagged exogenous YY1 and the lower band
indicates endogenous YY1.
(TIF)
Figure S2 VDJ rearrangements are similar in MigR1
vector and MigR1-FlagYY1 transduced B cells from
reconstituted animals. Rearrangement of various VH gene
families is shown comparing mice reconstituted with MigR1 vector
alone or MigR1-FlagYY1. V gene and DJ rearrangements are not
altered by YY1 expression.
(TIF)
Figure S3 Confirmation of YY1 overexpression micro-
array results by RT-PCR. Microarray results (black bars)
shown as fold change increase or decrease of MigR1-FlagYY1
transduced 38B9 cells relative to MigR1 vector alone, are
compared with fold changes measured by RT-PCR (stippled
bars). Error bars show the standard deviation of the mean. All
transcripts matched closely by the two methods except for nanog
expression which was induced to a much lower level as determined
by RT-PCR.
(TIF)
Figure S4 YY1 does not bind at the Bcl-xl or NFkB2
promoter areas. Chromatin made from murine 38B9 pro-B
cells was immunoprecipitated with YY1 antibody or rabbit IgG
control antibody. ChIP PCR was performed to detect the binding
of YY1 at Bcl-xl or NFkB2 promoter areas. 8 sets of primers were
designed to cover 1 kb of upstream promoter sequence of the Bcl-
xl gene, and 6 sets of primers were designed to cover the NFkB2
promoter. RpL30 was used as a positive control for YY1 binding,
and beta-actin was used as a negative control for YY1 binding.
The mean and standard deviation are shown.
(TIF)
Table S1 Real-Time PCR Primers.
(DOCX)
Table S2 Primers used for ChIP analyses.
(DOC)
Table S3 Microarray.
(XLS)
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